Aurobindo Pharma has received a final approval from the US Food & Drug Administration (USFDA) to manufacture and market Oxymorphone Hydrochloride Tablets, 5 mg and 10 mg. The approved ANDA is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) Opana (oxymorphone hydrochloride) Tablets, 5 mg and 10 mg, of Endo Pharmaceuticals, Inc.
Oxymorphone Hydrochloride Tablets is used to help relieve moderate to severe acute pain where the use of an opioid is appropriate. The approved product has an estimated market size of $55.5 million for the twelve months ending February 2016 according to IMS.
This is the 11th ANDA to be approved out of Aurolife formulation facility in New Jersey, USA for manufacturing Non-Antibiotic products & Controlled substances. Aurobindo now has a total of 257 ANDA approvals (220 Final approvals including 11 from Aurolife Pharma LLC and 37 tentative approvals) from USFDA.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1847.30 |
| Dr. Reddys Lab | 1293.25 |
| Cipla | 1347.70 |
| Zydus Lifesciences | 938.90 |
| Lupin | 2377.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: